Scholarlink

Background <p><i>Blastocystis</i> spp. is an anaerobic protozoan intestinal parasite, it comprises multiple subtypes (STs), with ST1 to ST9 being isolated from humans worldwide. Using polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP), these subtypes are classified into four groups (A to D). This study aimed to detect <i>Blastocystis</i> spp. groups in immunocompromised patients and evaluate their correlation with clinical presentations.</p> Materials and methods <p>A cross-sectional study was conducted on 150 immunocompromised patients and 50 immunocompetent individuals. All subjects were evaluated for socio-demographic data, clinical features, and parasitic infections. RFLP analysis of the SSU rRNA gene was performed for <i>Blastocystis</i> spp. grouping.</p> Results <p>Among 150 immunocompromised patients, <i>Blastocystis</i> spp. was detected in 83.3% by direct wet mount and 94.7% by PCR, showing significant difference (<i>P</i> = 0.003) compared to immunocompetent individuals (40% and 50%, respectively). Of the PCR-positive immunocompromised patients, 86.7% were symptomatic, with diarrhea being the most common symptom (66%). In immunocompromised patients, group B of <i>Blastocystis</i> spp. subtypes (ST3, ST4, and ST8) dominated (86.7%). On the other hand, just 12% of immunocompetent people had symptoms, with group A subtypes (ST1 and ST2) accounting for 38% of the study cases.</p> Conclusion <p><i>Blastocystis</i> spp. group B (ST3, ST4, and ST8) showed higher prevalence than group A (ST1 and ST2) in immunocompromised patients, with diarrhea being the most common clinical manifestation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Detection of Blastocystis species in immunocompromised patients (cancer, diabetes mellitus, and chronic renal diseases) by restriction fragment length polymorphism (RFLP)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月30日

查看全文
  • Manal Z. M. Abdellatif,
  • Ekhlas H. Abdel-Hafeez,
  • Usama S. Belal,
  • Noha H. Abdelgelil,
  • Heba Marey,
  • Manar M. S. A. Nasr,
  • Mohamed Mahmoud Abdel-Fatah

摘要

Background

Blastocystis spp. is an anaerobic protozoan intestinal parasite, it comprises multiple subtypes (STs), with ST1 to ST9 being isolated from humans worldwide. Using polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP), these subtypes are classified into four groups (A to D). This study aimed to detect Blastocystis spp. groups in immunocompromised patients and evaluate their correlation with clinical presentations.

Materials and methods

A cross-sectional study was conducted on 150 immunocompromised patients and 50 immunocompetent individuals. All subjects were evaluated for socio-demographic data, clinical features, and parasitic infections. RFLP analysis of the SSU rRNA gene was performed for Blastocystis spp. grouping.

Results

Among 150 immunocompromised patients, Blastocystis spp. was detected in 83.3% by direct wet mount and 94.7% by PCR, showing significant difference (P = 0.003) compared to immunocompetent individuals (40% and 50%, respectively). Of the PCR-positive immunocompromised patients, 86.7% were symptomatic, with diarrhea being the most common symptom (66%). In immunocompromised patients, group B of Blastocystis spp. subtypes (ST3, ST4, and ST8) dominated (86.7%). On the other hand, just 12% of immunocompetent people had symptoms, with group A subtypes (ST1 and ST2) accounting for 38% of the study cases.

Conclusion

Blastocystis spp. group B (ST3, ST4, and ST8) showed higher prevalence than group A (ST1 and ST2) in immunocompromised patients, with diarrhea being the most common clinical manifestation.